APO RESEARCH · REPORT
Stem Cell Therapy
Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.
Product & engineering
Understand the product.
Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.
Selected research
Market Outlook & Growth Opportunities
Global Stem Cell Therapy Market Outlook and Growth Opportunities 2026
Market perspective
Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.
North America is the largest Stem Cell Therapy market with about 65% market share. Europe is follower, accounting for about 16% market share.
The key players are Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix) etc. Top 3 companies occupied about 38% market share.
Read the full market overview
This report provides an overview of the global Stem Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Stem Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Stem Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Stem Cell Therapy market.
Stem Cell Therapy Segment by Company
Osiris Therapeutics
NuVasive
Chiesi Pharmaceuticals
JCR Pharmaceutical
Pharmicell
Medi-post
Anterogen
Molmed
Takeda (TiGenix)
Stem Cell Therapy Segment by Type
Autologous
Allogeneic
Stem Cell Therapy Segment by Application
Musculoskeletal Disorder
Wounds & Injuries
Cornea
Cardiovascular Diseases
Others
Stem Cell Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Stem Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Stem Cell Therapy key companies, revenue, market share, and recent developments.
3. To split the Stem Cell Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Stem Cell Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Stem Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Stem Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Stem Cell Therapy industry.
Chapter 3: Detailed analysis of Stem Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Stem Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Stem Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous
- Allogeneic
Applications
- Musculoskeletal Disorder
- Wounds & Injuries
- Cornea
- Cardiovascular Diseases
- Others
Companies covered
- Osiris Therapeutics
- NuVasive
- Chiesi Pharmaceuticals
- JCR Pharmaceutical
- Pharmicell
- Medi-post
- Anterogen
- Molmed
- Takeda (TiGenix)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Stem Cell Therapy Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Stem Cell Therapy Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Stem Cell Therapy Market Dynamics
- 2.1 Stem Cell Therapy Industry Trends
- 2.2 Stem Cell Therapy Industry Drivers
- 2.3 Stem Cell Therapy Industry Opportunities and Challenges
- 2.4 Stem Cell Therapy Industry Restraints
3 Stem Cell Therapy Market by Company
- 3.1 Global Stem Cell Therapy Company Revenue Ranking in 2025
- 3.2 Global Stem Cell Therapy Revenue by Company (2021-2026)
- 3.3 Global Stem Cell Therapy Company Ranking (2024-2026)
- 3.4 Global Stem Cell Therapy Company Manufacturing Base and Headquarters
- 3.5 Global Stem Cell Therapy Company Product Type and Application
- 3.6 Global Stem Cell Therapy Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Stem Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Stem Cell Therapy Market by Type
- 4.1 Stem Cell Therapy Type Introduction
- 4.1.1 Autologous
- 4.1.2 Allogeneic
- 4.2 Global Stem Cell Therapy Sales Value by Type
- 4.2.1 Global Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Stem Cell Therapy Sales Value by Type (2021-2032)
- 4.2.3 Global Stem Cell Therapy Sales Value Share by Type (2021-2032)
5 Stem Cell Therapy Market by Application
- 5.1 Stem Cell Therapy Application Introduction
- 5.1.1 Musculoskeletal Disorder
- 5.1.2 Wounds & Injuries
- 5.1.3 Cornea
- 5.1.4 Cardiovascular Diseases
- 5.1.5 Others
- 5.2 Global Stem Cell Therapy Sales Value by Application
- 5.2.1 Global Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Stem Cell Therapy Sales Value by Application (2021-2032)
- 5.2.3 Global Stem Cell Therapy Sales Value Share by Application (2021-2032)
6 Stem Cell Therapy Regional Value Analysis
- 6.1 Global Stem Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Stem Cell Therapy Sales Value by Region (2021-2032)
- 6.2.1 Global Stem Cell Therapy Sales Value by Region: 2021-2026
- 6.2.2 Global Stem Cell Therapy Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Stem Cell Therapy Sales Value (2021-2032)
- 6.3.2 North America Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Stem Cell Therapy Sales Value (2021-2032)
- 6.4.2 Europe Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Stem Cell Therapy Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Stem Cell Therapy Sales Value (2021-2032)
- 6.6.2 South America Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Stem Cell Therapy Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Stem Cell Therapy Country-level Value Analysis
- 7.1 Global Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Stem Cell Therapy Sales Value by Country (2021-2032)
- 7.2.1 Global Stem Cell Therapy Sales Value by Country (2021-2026)
- 7.2.2 Global Stem Cell Therapy Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.7.2 France Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.14.2 China Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.17.2 India Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Stem Cell Therapy Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Osiris Therapeutics
- 8.1.1 Osiris Therapeutics Company Information
- 8.1.2 Osiris Therapeutics Business Overview
- 8.1.3 Osiris Therapeutics Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.1.4 Osiris Therapeutics Stem Cell Therapy Product Portfolio
- 8.1.5 Osiris Therapeutics Recent Developments
- 8.2 NuVasive
- 8.2.1 NuVasive Company Information
- 8.2.2 NuVasive Business Overview
- 8.2.3 NuVasive Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.2.4 NuVasive Stem Cell Therapy Product Portfolio
- 8.2.5 NuVasive Recent Developments
- 8.3 Chiesi Pharmaceuticals
- 8.3.1 Chiesi Pharmaceuticals Company Information
- 8.3.2 Chiesi Pharmaceuticals Business Overview
- 8.3.3 Chiesi Pharmaceuticals Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.3.4 Chiesi Pharmaceuticals Stem Cell Therapy Product Portfolio
- 8.3.5 Chiesi Pharmaceuticals Recent Developments
- 8.4 JCR Pharmaceutical
- 8.4.1 JCR Pharmaceutical Company Information
- 8.4.2 JCR Pharmaceutical Business Overview
- 8.4.3 JCR Pharmaceutical Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.4.4 JCR Pharmaceutical Stem Cell Therapy Product Portfolio
- 8.4.5 JCR Pharmaceutical Recent Developments
- 8.5 Pharmicell
- 8.5.1 Pharmicell Company Information
- 8.5.2 Pharmicell Business Overview
- 8.5.3 Pharmicell Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.5.4 Pharmicell Stem Cell Therapy Product Portfolio
- 8.5.5 Pharmicell Recent Developments
- 8.6 Medi-post
- 8.6.1 Medi-post Company Information
- 8.6.2 Medi-post Business Overview
- 8.6.3 Medi-post Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.6.4 Medi-post Stem Cell Therapy Product Portfolio
- 8.6.5 Medi-post Recent Developments
- 8.7 Anterogen
- 8.7.1 Anterogen Company Information
- 8.7.2 Anterogen Business Overview
- 8.7.3 Anterogen Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.7.4 Anterogen Stem Cell Therapy Product Portfolio
- 8.7.5 Anterogen Recent Developments
- 8.8 Molmed
- 8.8.1 Molmed Company Information
- 8.8.2 Molmed Business Overview
- 8.8.3 Molmed Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.8.4 Molmed Stem Cell Therapy Product Portfolio
- 8.8.5 Molmed Recent Developments
- 8.9 Takeda (TiGenix)
- 8.9.1 Takeda (TiGenix) Company Information
- 8.9.2 Takeda (TiGenix) Business Overview
- 8.9.3 Takeda (TiGenix) Stem Cell Therapy Revenue and Gross Margin (2021-2026)
- 8.9.4 Takeda (TiGenix) Stem Cell Therapy Product Portfolio
- 8.9.5 Takeda (TiGenix) Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst